Urinary tract infections (UTIs) are common and contribute a significant burden to population health. In the United States, UTIs account for approximately 10 million ambulatory visits and an estimated $2 billion in total costs each year.1,2 Compared with men, women incur a greater burden of disease, with more than half of women experiencing at least 1 UTI during their lifetime.3 Among women aged 18 to 70 years, acute uncomplicated UTI results in nearly 4 days of genitourinary symptoms and 3 days of restricted activity per episode.4
Acute uncomplicated UTI or cystitis refers to symptomatic bladder infection in women without structural abnormalities, urinary instrumentation, or systemic diseases such as immunodeficiency.5 Worldwide, acute uncomplicated cystitis is one of the most common indications for antimicrobial prescriptions. In the past decade, more antibiotic prescriptions with varying lengths of treatment for cystitis6,7 have contributed to the emergence of multidrug-resistant uropathogens (eg, vancomycin-resistant Enterococci, extended-spectrum beta-lactamase–producing Enterobacteriaceae, and carbapenem-resistant Enterobacteriaceae).
No comments:
Post a Comment